NOVYRA
PHARMACHEM LIMITED

CIN NO. :- L21001GJ1987PLC171085
GST NO : 24AAACE6640F1Z0

November 02, 2026

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: - 519353

Dear Sir/Madam,

Sub: Outcome of the meeting of the Board of Directors held on November 02, 2026
Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the Company at their meeting held on today i.e. Monday, November 02, 2026 at the Registered Office of the Company ***inter-alia*** has, considered and approved the following: -

1. Un-Audited Financial Results of the Company for the Quarter and Half Year ended September 30, 2026, along with Auditors' Limited Reports, in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations.

2. Reviewed the business of the company.

The Board Meeting commenced at 4:30 P.M. and concluded at 5:15 P.M.

You are requested to take the above information on records and disseminate the same on your respective websites.

Thanking you,
Yours faithfully,

For, Novyra Pharmachem Limited
(formerly known as Bansisons Tea Industries Ltd)

For, Novyra Pharmachem Limited
Anil M. Amreliya
Director/Autho. Signatory

Anilkumar Mohanbhai Amreliya
Director
DIN : 11339148

NOVYRA PHARMACHEM LIMITED

R S No 432, City Survey No 3763,Ground Floor,Pavthawala Compound B/h ZenithMill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat, India,395004

CIN : L21001GJ1987PLC171085

Statement of unaudited Assets and liabilities as on September 30th, 2026

(Rs.in lakhs)

	Particulars	Year ended	
		30-09-2025	31/03/2026
A.	Date of Start of the reporting period	01/04/2026	01/04/2025
B.	Date of end of the reporting period	30/09/2026	31/03/2026
C.	Whether results are audited or unaudited	Unaudited	Audited
	ASSETS		
1	**Non-current assets**		
a)	Property, Plant and Equipment	117.76	74.09
b)	Capital work-in-progress	-	-
c)	Investment Property	-	-
d)	Goodwill	-	-
e)	Other Intangible assets	-	-
f)	Intangible assets under development	-	-
g)	Biological Assets other than bearer plants	-	-
h)	Investments accounted for using equity method	-	-
i)	Financial Assets		
(i)	Investments		
(ii)	Trade receivables		
(iii)	Loans Receivable	-	-
(iv)	Security Deposits	-	-
i)	Deferred tax assets (net)		
j)	Other non-current assets		
	Total Non-current assets	**117.76**	**74.09**
2	Current assets		
a)	Inventories	8.27	-
b)	Financial Assets		
(i)	Investments	-	-
(ii)	Trade receivables	157.45	1.08
(iii)	Cash and cash equivalents	23.28	14.72
(iv)	Bank balances other than Cash and cash equivalents		-
(v)	Short Term Loans & Advances	0.08	44.37
(vi)	Others		-
c)	Current Tax Assets (Net)		-
d)	Other current assets	14.86	11.62
3	Non-current assets classified as held for sale		
4	Regulatory deferral account debit balances and related deferred tax assets		
	Total Current Assets	**203.94**	**71.79**
	Total Assets	321.70	145.88
	EQUITY & LIABILITIES:		
	Equity		
a)	Equity Share capital	633.00	630.00
b)	Other Equity	(576.11)	(570.79)
	Total Equity	**56.89**	**59.21**
	Liabilities		
1)	**Non-Current Liabilities**		
a)	Financial Liabilities		-
(i)	Long Term Borrowings		-
(ii)	Trade payables		-
(iii)	Other financial liabilities (other than those specified in item (b), to be specified)		-
b)	Provisions		-
c)	Deferred tax liabilities (Net)		-
d)	Deferred government grants (non current)		-
e)	Other non-current liabilities		-
2)	Current liabilities		
a)	Financial Liabilities		

(i)	Short Term Borrowings		
(ii)	Trade payables		
	Total Outstanding Dues of creditors micro and small enterprise		
	Total Outstanding Dues of creditors other than micro and small enterprise	261.63	86.67
(iii)	Other financial liabilities	0.19	-
a)	Provisions	2.99	-
b)	Income/Current Tax Liabilities (Net)		
c)	Other current liabilities		
	Total Current Liabilities	264.81	86.67
	Total Liabilities	**321.70**	**145.88**

For, NOVYRA PHARMACHEM LIMITED

For, Novyra Pharmachem Limited

Anil M Amreliya

Director/Autho. Signatory

Anilkumar Mohanbhai Amreliya

Director

DIN: 11339148

Date :- 02-11-2026

Place :- Surat

NOVYRA PHARMACHEM LIMITED

R S No 432, City Survey No 3763,Ground Floor,Pavthawala Compound B/h ZenithMill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat, India,395004

CIN : L21001GJ1987PLC171085

Statement of unaudited Standalone Financial Results for the Quarter ended September 30, 2026

(Rs. In Lakhs)

	Particulars	Quarter Ended			Half Year Ended		For The Year Ended
		30/09/2026	30/06/2026	30/09/2024	30/09/2026	30/09/2025	31/03/2026
A	Date of start of reporting period	01/07/2026	01/04/2026	01/07/2025	01/04/2026	01/04/2025	01/04/2025
B	Date of end of reporting period	30/09/2026	30/06/2026	30/09/2025	30/09/2026	30/09/2025	31/03/2026
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Revenue From Operations						
	(a) Revenue From Operations	423.08	172.61	-	595.69	-	10.44
	(b) Other Income	3.70	-	3.31	3.70	6.31	6.31
					-	-	
	Total Revenue from operations (net)	**426.78**	**172.61**	**3.31**	**599.39**	**6.31**	**16.75**
	Expenditure						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchases of stock-in-trade	414.02	189.13	-	603.15	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	9.54	-17.81	-	(8.27)	-	-
	(d) Employee benefit expense	2.42	0.60	1.46	3.02	2.87	15.06
	(e) Finance Costs	-	-	-	-	-	-
	(e) Depreciation and amortisation expense	0.30	0.30	0.73	0.60	1.45	2.89
	(f) Other Expenses	3.83	2.38	1.03	6.21	2.67	536.17
		-					
	Total expenses	**430.10**	**174.60**	**3.21**	**604.70**	**6.98**	**554.13**
	Profit (loss) Before exceptional & Extraordinary items and Tax	**(3.32)**	**(1.99)**	**0.10**	**(5.31)**	**(0.67)**	**(537.38)**
	Exceptional items	-	-		-	-	
	Profit (loss) from ordinary activities before tax	**(3.32)**	**(1.99)**	**0.10**	**(5.31)**	**(0.67)**	**(537.38)**
	Tax Expenses - Current Tax	-	-		-	-	
	(less):· MAT Credit	-	-	-	-	-	-
	Current Tax Expense Relating to Prior years	-	-	-	-	-	-
	Deferred Tax (Assets)/llabtlltles				-	-	
	Profit (loss) from ordinary activities	**(3.32)**	**(1.99)**	**0.10**	**(5.31)**	**(0.67)**	**(537.38)**
	Other Comprehensive Income (OCI)	-	-				
		-	-				
	Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
		-	-	-	-	-	-
	Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
		-	-				
	Total Profit After Other Comprehensive Income	**(3.32)**	**(1.99)**	**0.10**	**(5.31)**	**(0.67)**	**(537.38)**
	Profit/(Loss) From Discountinuing Operation Before Tax	-	-		-	-	
	Tax Expenses of Discontinuing Operations	-	-		-	-	
	Net Profit/(Loss) from Discountinuing Opration After Tax	-	-	-	-	-	-
	Profit(Loss) For Period Before Minority Interest	-	-	-	-	-	-
	Share Of Profit / Loss Associates	-	-		-	-	
	Profit/Loss Of Minority Interset	-	-		-	-	
	Net Profit (+)/ Loss (-) For the Period	**(3.33)**	**(1.99)**	**0.10**	**(5.31)**	**(0.67)**	**(537.38)**
	Details of equity share capital				-	-	
	Paid-up equity share capital	633.00	633.00	630.00	633.00	630.00	633.00
	Face value of equity share capital (per share)	10.00	10.00	10.00	10.00	10.00	10.00
	Reserve Excluding Revaluation Reserves As Par Balance sheet Of previous Year			-	-		-
	Earnings per share (EPS)				-		
	Basic earnings per share from countinuing And Discountinuing operations	(0.05)	(0.03)	0.00	(0.08)	(0.01)	(8.49)
	Diluted earnings per share from countinuing And Discountinuing operations	(0.05)	(0.03)	0.00	(0.08)	(0.01)	(8.49)

Notes:-

1	The above said finanical results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective Meetings held on 11th October , 2025.
2	The Statutory Auditors have carried out limited review of the Unaudited Results of the Company for the Quarter ended 30/09/2025.

3	These results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") 34 - Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules as amended from time to time.
4	The Company has no reportable business segment. Hence, separate information for segment wise disclosure is given in accordance with the requirements of Ind AS (AS) 108 -
5	Statement of Assets and Liabilities and cashflow statement as on 30th September 2025 is enclosed herewith.
6	The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

For, NOVYRA PHARMACHEM LIMITED

For, Novyra Pharmachem Limited

Anil M Amreliya

Director/Autho. Signatory

Anilkumar Mohanbhai Amreliya
Director
DIN: 11339148

Date :- 02-11-2026
Place :- Surat

NOVYRA PHARMACHEM LIMITED

R S No 432, City Survey No 3763,Ground Floor,Pavthawala Compound B/h ZenithMill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat, India,395004

CIN : L21001GJ1987PLC171085

Unaudited Cash Flow Statement for the half year ended September 30, 2026

	Particulars	As on 30th September, 2026 Rs. In Lakhs	As on 31st March, 2026 Rs. In Lakhs
A.	**Cash flow from operating activities**		
	Profit before Tax	(5.31)	(537.38)
	Adjustments for:		-
	Depreciation and amortisation	0.60	2.89
	Interest Income	-	(6.31)
	Finance costs	-	-
	Loss on sale of Investment	-	-
	Operating profit / (loss) before working capital changes	**(4.71)**	**(540.80)**
	Movements in Working Capital		
	(Increase) / Decrease Inventories	(8.27)	0.00
	(Increase) / Decrease Short-term loans and advances	-	-
	Increase / (Decrease) Trade payables	174.96	82.34
	(Increase) / Decrease Trade Receivables	(156.37)	4.93
	(Increase) / Decrease Other Non Current Assets	-	-
	(Increase) / Decrease Other Current Assets (Provisions)	2.99	1.50
	(Increase) / Decrease Other Current Assets	(3.24)	(11.72)
	(Increase) / Decrease Other Non Current Liabilities	-	-
	Increase / (Decrease) Short Term Borrowings	-	-
	Increase / (Decrease) Short Term Provisions	-	-
	Increase / (Decrease) Other current Assets (Loans)	44.28	85.13
	Increase / (Decrease) Other financial liabilities	0.19	-
	Net Cash Generated/(Used in) Operations	**54.55**	**162.19**
	Cash flow from extraordinary items	-	-
	Direct Taxes Paid including for past years	-	-
	Dividend & Dividend Tax Paid	-	-
	Net cash flow from / (used in) operating activities (A)	**49.84**	**(378.61)**
B.	**Cash flow from Investing activities**		
	Sale / (Purchase) of Fixed Assets	(44.28)	371.65
	Interest received	-	6.31
	Dividend Received	-	
	Investment in Security deposits	-	6.68
	Purchase of Investments	-	-
	Sale of Investments	-	0.36
	Investment in Joint Venture	-	-
	Change in Current Investment	-	-
	Change in Long Term Loan and Advances	-	-
	Change in Non-Current Assets	-	-
	Change in Non-Current Investment	-	-
	Net cash flow from / (used in) investing activities (B)	**-44.28**	**384.99**
C.	**Cash flow from financing activities**		
	Increase in Share Capital	-	
	Increase / (Decrease) Short Term Borrowings	-	(15.00)
	Net cash flow from / (used in) financing activities (C)	**0.00**	**(15.00)**
	Net increase / (decrease) in Cash and cash equivalents (A+B+C)	**5.56**	**-8.62**
	Cash and cash equivalents at the beginning of the year	17.72	26.34
	Cash and cash equivalents at the end of the year *	**23.28**	**17.72**
	*** Comprises:**		
	(a) Cash on hand	15.60	14.08
	(b) Balances with banks		
	(i) In current accounts	7.68	3.64

(ii) In deposit accounts		-
	23.28	17.72

For, NOVYRA PHARMACHEM LIMITED
For, Novyra Pharmachem Limited

Anil M Amreliya

Director/Autho. Signatory
Anilkumar Mohanbhai Amreliya
Director
DIN: 11339148

Date: 02-11-2026
Place: Surat

NOVYRA PHARMACHEM LIMITED

R S No 432, City Survey No 3763,Ground Floor,Pavthawala Compound B/h ZenithMill, Vastadevadi Road, Vasta Devdi Road, Surat, Gujarat, India,395004

CIN : L21001GJ1987PLC171085

Reporting of Segment wise Revenue, Results and Capital Employed along financial results for the Quarter Ended on June 30, 2026

(In Lakh except per share data)

	Particulars	Quarter Ended			For The Year Ended
		30/09/2026	30/06/2026	30/09/2025	31/03/2026
A	Date of start of reporting period	01/07/2026	01/04/2026	01/07/2025	01/04/2025
B	Date of end of reporting period	30/09/2026	30/06/2026	30/09/2025	31/03/2026
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	**Segment Revenue** (net sale/income from each segment should be disclosed under this head)				
(a)	Segment - Pharma	423.08	172.61	-	1.00
(b)	Segment - Real Estate	3.70	-	-	3.50
(c)	Segment - Tea Estate	-	-	-	12.25
(d)	Segment - Unallocable	-	-	3.31	-
					-
	Total	**426.78**	**172.61**	**3.31**	**16.75**
	Less: Inter Segment Revenue		-	-	-
	Net sales/Income From Operations	**426.78**	**172.61**	**3.31**	**16.75**
2	**Segment Results (Profit)(+)/ Loss (-) before tax and Interest from Each segment)#**				
(a)	Segment - Pharma	3.20	1.29		1.00
(b)	Segment - Real Estate	-	-	-	3.50
(c)	Segment - Tea Estate	-	-	-	(446.64)
(d)	Segment - Unallocable	(6.52)	(3.28)	0.10	(95.24)
					-
	Total	**(3.32)**	**(1.99)**	**0.10**	**(537.38)**
	Less:	-	-	-	-
	Finance Cost	-			
	Other Un-allocable Expenditure net off	-		-	
	Un-allocable income		-	-	
	Total Profit Before Tax	**(3.32)**	**(1.99)**	**0.10**	**(537.38)**
					-
3	**Capital Employed (Segment assets - Segment Liabilities)**				
3(1)	**Segment Assets**				
(a)	Segment - Pharma	165.72	197.39	-	1.08
(b)	Segment - Real Estate	23.25	23.25	-	44.27
(c)	Segment - Tea Estate	94.51	94.80	612.27	74.09
(d)	Segment - Unallocable	24.82	16.33	-	26.44
	Total	**308.30**	**331.77**	**612.27**	**145.88**
3(2)	**Segment Liabilities**				
(a)	Segment - Pharma	261.40	279.80	-	82.34
(b)	Segment - Real Estate	-	-	-	
(c)	Segment - Tea Estate	-	-	19.42	
(d)	Segment - Unallocable	(10.00)	(8.24)	3.30	4.34
	Total	**251.40**	**271.56**	**22.72**	**86.68**

FOR NOVYRA PHARMACHEM LIMITED

For, Novyra Pharmachem Limited

Anil M Amreliya

Director/Autho. Signatory

Anilkumar Mohanbhai Amreliya
Director
DIN: 11339148

Date :- 02-11-2026
Place :- Surat

D G M S & Co.
Chartered Accountants

Hiren J. Maru
B.Com., F.C.A., DISA, DIRM

Independent Auditor's Review Report on Quarterly and Half Yearly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (as amended)

To Board of Directors of
NOVYRA PHARMACHEM LIMITED
(Formerly Known as Bansisons Tea Industries Limited)

We have reviewed the accompanying statement of unaudited financial results of NOVYRA PHARMACHEM LIMITED (Formerly known as Bansisons Tea Industries Ltd) (the "Company") for the quarter and half year ended September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors at their meeting held on 02nd November 2026, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" (Ind AS 34), as prescribed under section 133 of the Companies Act, 2013 as amended, read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review of the Statement conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR D G M S & CO.
Chartered Accountants
Firm Regn. No. 0112187W

D G M S & CO. Chartered Accountants FRN: 0112187W

Hiren Maru
Partner
Membership No. 115279
UDIN: 26115279ZZJLMN1858
Date: 2nd November 2026
Place: Thane

Office Address: Office No. 10, Vihang Vihar, Opp. Gautam Park, Panchpakhadi, Thane (West) – 400 602, Maharashtra, India.
Cell: +91 9320268900 Ph.: 022 4601 2965 / 2545 2965 Email: hirenmaru@yahoo.co.uk